Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kemp Dolliver has downgraded Cyclacel Pharmaceuticals (NASDAQ:CYCC) from Buy to Hold, indicating a shift in the firm's outlook on the stock.

December 19, 2023 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cyclacel Pharmaceuticals was downgraded by Brookline Capital from Buy to Hold, which may lead to a neutral or slightly negative investor sentiment in the short term.
Downgrades by analysts can often lead to a negative short-term reaction in the stock market as they may reflect a less optimistic view on the company's future performance or valuation. The downgrade from Buy to Hold suggests that the analyst no longer sees the stock as an outperforming investment, which could lead to decreased investor confidence and a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100